Navigation Links
Amsterdam Molecular Therapeutics Reports Full Year Results 2007
Date:2/19/2008

d by law. For a more detailed description of the risk factors and uncertainties affecting AMT, refer to the prospectus of AMT's initial public offering on June 20, 2007, and AMT's public announcements made from time to time.

Consolidated income statement

(In EUR x 1,000)

Year ended

31 December 2007 31 December 2006

Revenues - 52

Cost of sales - 42

Gross profit - 10

Other income 110 417

Total net income 110 427

Research and development costs (9,804) (5,342)

General and administrative costs (4,966) (4,169)

Total operating costs (14,770) (9,511)

Operating result (14,660) (9,084)

Interest income 1,406 14

Interest costs (1,681) (803)

(275) (789)

Result on deconsolidation - 1,113

Result before corporate income taxes (14,935) (8,760)

Corporate income taxes - -

Result for the year (14,935) (8,760)

Attributable to:

Equity holders of the Company (14,935) (8,760)

Result attributable to equity holders is

split as follows:

Ordinary shareholders
'/>"/>

SOURCE Amsterdam Molecular Therapeutics B.V
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Amsterdam Molecular Therapeutics to Appoint Philippe van Holle (Celgene) to Supervisory Board
2. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
3. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
4. Molecular Diagnostics Leader AdvanDx Taps Former Dako Executive Vice President to Lead Global Sales and Marketing Expansion
5. Acrongenomics on Track to Acquire Molecular Vision
6. Vermillion and Johns Hopkins Sign Collaborative Research and License Agreements to Develop Molecular Diagnostic Tests
7. Acrongenomics Acquires Equity Stake in Molecular Vision
8. The Dark Report and Siemens Introduce the Worlds First Integrated Molecular Summit
9. The Center for Molecular Medicine Doubles Lab Staff, Expands Lab Space by 100 Percent
10. Peakdale Molecular Announces GBP 1 Million Funding to Support Expansion and Growth
11. Center for Molecular Medicine Selected to Provide DNA Analysis for Childrens Oncology Group Leukemia Study
Post Your Comments:
*Name:
*Comment:
*Email: